The Global Large Molecule Drug Substance CDMO Market is Predict to reach $19.2 Billion by 2028, at a CAGR of 8.7%

Published Date: 20-Jan-2023

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Large Molecule Drug Substance CDMO Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Large Molecule Drug Substance CDMO Market size is expected to reach $19.2 billion by 2028, rising at a market growth of 8.7% CAGR during the forecast period.

The Mammalian segment acquired maximum revenue share in the Global Large Molecule Drug Substance CDMO Market by Application in 2021 thereby, achieving a market value of $10.8 billion by 2028. The segment is expanding with the growth in antibody-drug conjugates and complex biologics like tri- and bi-specific antibodies. In addition, large molecules like monoclonal antibodies (mAbs) and their synthetic equivalents are receiving immense attraction that is owed to their high effectiveness and versatility in treating numerous diseases.

The Contract Development segment has shown the growth rate of 10.9% during (2022 - 2028). Contract development most commonly involves process development and cell line development. Both of these process form the base for the development and assembling of drugs. CDMOs help biopharmaceutical companies by providing services for upstream and downstream processes along with a wide range of analytical methods to assist in bioassays and protein characterization.

The Biotech Companies segment is leading the Global Large Molecule Drug Substance CDMO Market by End-user in 2021 thereby, achieving a market value of $8.6 billion by 2028. The growth of the segment is mainly attributed to the rising R&D investments. The increasing prevalence of various diseases has necessitated extensive research for the facilitation of drug candidates. Additionally, many biotech firms are aiming at increasing their product range to remain prominent in the biopharmaceutical industry.

The Asia Pacific market dominated the Global Large Molecule Drug Substance CDMO Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $7 billion by 2028. The Europe market is experiencing a CAGR of 8.4% during (2022 - 2028). Additionally, The North America market would display a CAGR of 8% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/large-molecule-drug-substance-cdmo-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.

Global Large Molecule Drug Substance CDMO Market Segmentation

By Application

  • Mammalian
  • Microbial
  • Others

By Service

  • Contract Manufacturing
    • Commercial
    • Clinical
  • Contract Development
    • Cell Line Development
    • Process Development

By End-user

  • Biotech Companies
  • CRO
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Eurofins Scientific SE
  • WuXi Biologics (Cayman), Inc
  • Catalent, Inc.
  • Boehringer Ingelheim International GmbH
  • FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
  • Samsung Biologics Co., Ltd. (Samsung Group)
  • Rentschler Biopharma SE
  • AGC Biologics, Inc. (AGC, Inc.)
  • Recipharm AB (EQT AB)
  • Siegfried Holding AG

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

North America Large Molecule Drug Substance CDMO Market Future Scope & Opportunities 2022-2028

Europe Large Molecule Drug Substance CDMO Market Size & Growth Forecast 2022-2028

Asia Pacific Large Molecule Drug Substance CDMO Market Size, Share & Industry Outlook to 2028

LAMEA Large Molecule Drug Substance CDMO Market Growth, Trends & Forecasts 2022-2028

Request a Free Sample Copy


Why Choose Us

  • 24/7 Research support
    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Information security
    Your personal and confidential information is safe and secure.